Asthma is controllable but continues to impose a considerable health burden on the U.S. population, especially on poor and non-white adolescents. While evidence-based clinical care is essential, inadequate patient self-management is a major contributor to excess morbidity.

Responding to this critical need, our research team has developed and piloted an innovative brief behavioral intervention that combines proven behavioral technology with tailored text-messaging to reduce asthma symptoms. Our preliminary data suggests that this In Vivo intervention is promising. 


The main objective of this study is to determine the efficacy of the In Vivo intervention in reducing asthma symptoms in adolescents in a randomized control trial comparing the In Vivo intervention to usual care.


The specific aims: Determine the efficacy of the In Vivo intervention on our primary outcome – asthma symptoms – for adolescents with asthma. Determine the efficacy of the In Vivo intervention on our secondary outcomes – asthma symptom days, the Asthma Control Test, exacerbations, utilization, and health-related quality of life (HRQOL) – and evaluate the durability of the effect. Determine the mechanism of effect for the In Vivo intervention.

Expected Outcomes

This research will yield the following expected outcomes:

  1. Evidence concerning the clinical and statistical efficacy of the intervention, including the duration of effect and the mechanism of effect.
  2. A complete shared data set for further scientific inquiry.
  3. Materials for practitioners including field-tested intervention materials and manuals.

Evidence for the efficacy of such an intervention could have a substantial impact on the health outcomes of at-risk adolescents with asthma throughout the U.S. Moreover, as the intervention is not condition-specific, it could have broad application across populations and diseases.

View more information about this study on the NIH website.